Pulsenmore Ltd.
PLSM · Surgical & Medical Instruments & Apparatus · EDGAR filings ↗
Grade
D48Israeli home-ultrasound device maker with explosive revenue growth and a fresh FDA clearance, but deep losses and a critically short cash runway.
Strengths
- Revenue up 374% (98.1st pct) and gross margin 84% (90th); FDA Class II clearance for Pulsenmore ES in Oct 2025
- Current ratio 7.9 and quick ratio 5.9 at period end
Risks
- Cash runway just 2.6 quarters (37.5th) with FCF -$10.3M — acute funding/dilution risk
- Net margin -40%, ROE -19%; heavy dependence on Clalit and early-stage commercialization
Notable findings
- Net lossNet loss (net margin -39.6%)
- Cash burnNegative free cash flow (-10.3M)
- FDA approvalFDA clearance/approval — Pulsenmore ES (2025-10-31)
Key metrics
Gross margin
84.2%
Net margin
-39.6%
Return on equity
-19.1%
Return on assets
-15.6%
Revenue growth (QoQ)
373.6%
Current ratio
7.9×
Free cash flow
-$10M
Tangible book value
$26M
Cash & investments
$7M
Cash runway
3q
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 20-F | 2026-03-30 | 2025-12-31 | 0001493152-26-013485 ↗ |